Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Atorvastatin Calcium in Medication interactions: NCT07785934 Clinical Landscape Report 2026
18 September 2026
NCT07785934 clinical landscape for Medication interactions: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iparomlimab/Tuvonralimab in Locally Advanced Rectal Carcinoma: NCT07769853 Clinical Landscape Report 2026
18 September 2026
NCT07769853 clinical landscape for Locally Advanced Rectal Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Empagliflozin/metformin Hydrochloride in Diabetes Mellitus, Type 2: NCT07771010 Clinical Landscape Report 2026
18 September 2026
NCT07771010 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pucotenlimab in Squamous cell carcinoma of the oral cavity: NCT07766889 Clinical Landscape Report 2026
18 September 2026
NCT07766889 clinical landscape for Squamous cell carcinoma of the oral cavity: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Sintilimab in Locally Advanced Head and Neck Squamous Cell Carcinoma: NCT07781072 Clinical Landscape Report 2026
18 September 2026
NCT07781072 clinical landscape for Locally Advanced Head and Neck Squamous Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and…
9 min read
Vitamin E/Ascorbic Acid in Neuroinflammation: NCT07782411 Clinical Landscape Report 2026
18 September 2026
NCT07782411 clinical landscape for Neuroinflammation: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Boswellia serrata extract in Radiodermatitis: NCT07778290 Clinical Landscape Report 2026
18 September 2026
NCT07778290 clinical landscape for Radiodermatitis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Semaglutide (Novo Nordisk) in Obesity: NCT07783854 Clinical Landscape Report 2026
18 September 2026
NCT07783854 clinical landscape for Obesity: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
8 min read
HX-044 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
HX-044: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
XMVA-09 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
XMVA-09: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
ANOC-002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
ANOC-002: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
PNB-028 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
PNB-028: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.